Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multi-dosing BCG Vaccine for Fibromyalgia
NCT03582085Phase 2Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2026
- Primary completion
- Jan 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of bcg vaccine in fibromyalgia (FM), sponsored by Massachusetts General Hospital. Planned start Jan 2026; status: withdrawn.
02
Drugs
bcg vaccine
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on NCT03582085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03582085.